Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Kína3. fázis

Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

A legfontosabb adatok

Ki végzi
Tasly Pharmaceutical Group Co., Ltd
Hol
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Sanmenxia, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Xianyang és Yangquan (Kína)Mind a 30 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
520 fő, tervezett
Kezdés
2024. dec. 30.
Várható befejezés
2026. dec. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Changkang granules
  • Changkang Granules placebo
A regiszteradat frissítve
2024. december 31.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with irritable bowel syndrome where diarrhea is the main problem. They must also have the Traditional Chinese Medicine pattern called Liver qi affecting the spleen.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Irritable bowel syndrome with mainly diarrhea (Rome IV criteria). Weekly average abdominal pain score (NRS) of 3.0 or more during the run-in period. At least 2 days per week with stool type 6 or 7 on the Bristol Stool Scale. IBS-SSS score above 175 at the start.
Korábbi kezelés
A colonoscopy in the past 12 months, normal or with only small findings the doctor accepts. No prokinetic agents, anticholinergic drugs, calcium channel blockers (except for blood pressure), 5-HT3 receptor antagonists, antidiarrheals, antidepressants, anxiolytics, probiotics, painkillers or laxatives within 4 weeks before randomization. No rescue medication (piroxicam) during the run-in period.

A részvétel fő kizáró okai

  • Other gut diseases, such as inflammatory bowel disease, ulcers, cirrhosis or digestive system tumors
  • Severe mental illness, or a depression score of 63 or more (SDS) or anxiety score of 60 or more (SAS)
  • Diabetes, thyroid disease, chronic kidney problems or autoimmune diseases
  • Major abdominal surgery, or ALT or AST above 1.5 times the upper limit of normal, or raised creatinine
  • Pregnant or breastfeeding women, or those planning pregnancy during the trial

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must meet all of the following inclusion criteria to be eligible for this trial:; Age 18-65 years (inclusive), regardless of gender; Meet the Western medical diagnostic criteria for Irritable Bowel Syndrome with Predominant Diarrhea (Rome IV); Meet the Traditional Chinese Medicine diagnostic criteria for Liver qi affecting the spleen pattern; Have a weekly average NRS score for abdominal pain ≥3.0 during the Run-In Period period, and have at least 2 days per week with stool form of type 6 or 7 (Bristol Stool Scale) during the Run-in period; Have an IBS-SSS score >175 at baseline; Have completed a colonoscopy within the past 12 months prior to the Run-in period, and meet one of the following conditions: ① Normal colonoscopy results with no organic changes; ② Abnormal colonoscopy report, such as hemorrhoids, polyps (diameter ≤5mm and number ≤3), etc., which the investigator determines can be included; ③ Previous colonoscopy report indicating polyps >5mm in diameter or >3 in number, which after endoscopic treatment 6 months ago, residual polyps are ≤5mm in diameter and ≤3 in number, and the investigator determines can be included; Voluntarily sign the informed consent form, and from the time of signing the informed consent form until the end of the last visit of the trial, the participant voluntarily accepts health education and maintains their usual diet and lifestyle, such as not changing dietary structure or exercise patterns

Ki nem vehet részt

  • Subjects with any of the following conditions are not eligible for enrollment in this study:; Subjects who have less than 3 spontaneous bowel movements per week during the run-in period; or at least 2 days per week during the run-in period with stool consistency classified as type 1 or 2 on the Bristol Stool Scale; Patients with a history of severe mental or psychological disorders, or those scoring ≥63 on the Self-Rating Depression Scale (SDS), or ≥60 on the Self-Rating Anxiety Scale (SAS) during the screening period; Patients with a confirmed history of organic gastrointestinal diseases, including both gastrointestinal and non-gastrointestinal digestive system diseases, such as chronic superficial gastritis with erosions or bleeding of grade II or higher, chronic atrophic gastritis, peptic ulcers, inflammatory bowel disease, intestinal tuberculosis, intestinal ulcers, intestinal obstruction, intestinal adhesions, eosinophilic gastroenteritis, cholelithiasis with recurrent cholecystitis (patients with gallstones or gallbladder polyps ≤0.5 cm in diameter and no significant symptoms may be exempted from exclusion upon investigator's judgment), tuberculous peritonitis, liver cirrhosis, and digestive system tumors, etc; Patients diagnosed with other diseases that affect the evaluation of abdominal pain and diarrhea, such as diarrhea caused by lactose intolerance, diarrhea after cholecystectomy, abdominal pain due to endometriosis, abdominal pain caused by hepatic and biliary stones or cholecystitis, abdominal pain due to chronic pancreatitis, etc; Patients with a history of systemic diseases affecting gastrointestinal function, such as diabetes mellitus, hyperthyroidism or hypothyroidism, chronic renal insufficiency, autoimmune diseases (such as allergic colitis, allergic purpura, Behcet's syndrome, systemic lupus erythematosus), etc; Patients with a history of major abdominal surgery involving the gastrointestinal tract, liver, gallbladder, spleen, or pancreas (subjects who have undergone appendectomy or cesarean section without impact on gut function may be exempted from exclusion upon investigator's judgment); Patients with unexplained recurrent positive fecal occult blood, unintentional weight loss, anemia, fever, or jaundice prior to screening; Abnormal liver function at baseline (ALT or AST >1.5 times the upper limit of normal) or abnormal renal function at baseline (Cr >upper limit of normal); Patients with a history of severe diseases in the respiratory, cardiovascular, cerebral, hepatic, renal, endocrine, immune, hematopoietic systems, as well as tumors and neurological diseases, deemed unsuitable for participation in this trial by the investigator; Patients who have used prokinetic agents, anticholinergic drugs, calcium channel blockers (excluding antihypertensive drugs), 5-HT3 receptor antagonists, antidiarrheals, antidepressants, anxiolytics, probiotics, analgesics, laxatives, etc., within 4 weeks before randomization; Patients who took rescue medication (piroxicam) during the run-in period; Pregnant or breastfeeding women, or those planning to conceive within 1 month after enrollment until the end of the trial; Patients suspected or known to be allergic to the investigational drug, rescue medication, or its components; Patients suspected or known to have a history of alcohol or drug abuse; Patients who participated in another interventional clinical trial and took investigational drugs within 1 month before screening; Patients whom the investigator deems unsuitable for clinical trial participation for any other reason

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Helyszínek itt: Kína

  • Baoding First Traditional Chinese Medicine HospitalBaoding, KínaContact: Lipu WangToborzás még nem indult
  • No. 5, Beixiange Street, Xuanwu District, BeijingBeijing, KínaContact: Zhen LiuToborzás még nem indult
  • The Second Affiliated Hospital of Hunan University of Chinese MedicineChangsha, KínaContact: Juan ni ZengToborzás még nem indult
  • Changde Second People's HospitalChengde, KínaContact: Xianyi WangToborzás még nem indult
  • Chengdu Shuangliu District First People's HospitalChengdu, KínaContact: Mei Hua WanToborzás még nem indult
  • Sichuan University West China HospitalChengdu, KínaContact: Wenfu TangToborzás még nem indult
  • Guangzhou First People's HospitalGuangzhou, KínaContact: Rui LiuToborzás még nem indult
  • Zhejiang Provincial Tongde HospitalHangzhou, KínaContact: Baoying FeiToborzás még nem indult
  • Zhejiang Xinhua HospitalHangzhou, KínaContact: Jihong ZhongToborzás még nem indult
  • Kaifeng City Traditional Chinese Medicine HospitalKaifeng, KínaContact: Qinghua ZhaoToborzás még nem indult
  • Gansu Provincial Hospital of Traditional Chinese MedicineLanzhou, KínaContact: Xudong TianToborzás még nem indult
  • Luoyang Central HospitalLuoyang, KínaContact: Hongwei ChenToborzás még nem indult
  • Luoyang First People's HospitalLuoyang, KínaContact: Hongling LiuToborzás még nem indult
  • Jiangxi University of Traditional Chinese Medicine Affiliated HospitalNanchang, KínaContact: Ling HeToborzás még nem indult
  • Nanjing Traditional Chinese Medicine HospitalNanjing, KínaContact: Qin YangToborzás még nem indult
  • Guangxi Traditional Chinese Medicine University Affiliated Rui Kang HospitalNanning, KínaContact: Tao ZhangToborzás még nem indult
  • Sanmenxia Central HospitalSanmenxia, KínaContact: Xuemin ZhaiToborzás még nem indult
  • Shanghai University of Traditional Chinese Medicine Affiliated Longhua HospitalShanghai, KínaContact: Jiang LinToborzás még nem indult
  • Liaoning University of Traditional Chinese Medicine Third Affiliated HospitalShenyang, KínaContact: Yue Dong LiuToborzás még nem indult
  • Hebei Provincial Hospital of Traditional Chinese MedicineShijiazhuang, KínaContact: Qian YangToborzás még nem indult
  • Hebei Provincial People's HospitalShijiazhuang, KínaContact: Gaifang LiuToborzás még nem indult
  • Tianjin University of Traditional Chinese Medicine Second Affiliated HospitalTianjin, KínaContact: Hui Zhen LiToborzás még nem indult
  • Wenzhou Medical University Affiliated Second HospitalWenzhou, KínaContact: Dingyuan HuToborzás még nem indult
  • Wenzhou Traditional Chinese Medicine HospitalWenzhou, KínaContact: Yaoming ZengToborzás még nem indult
  • Huazhong University of Science and Technology Tongji Medical College Affiliated Union HospitalWuhan, KínaContact: Heng FanToborzás még nem indult
  • Hubei Provincial Hospital of Traditional Chinese MedicineWuhan, KínaContact: Yunlian HuToborzás még nem indult
  • Shanxi Provincial Hospital of Traditional Chinese MedicineXi'an, KínaContact: tao YuToborzás még nem indult
  • Shanxi University of Chinese Medicine Affiliated HospitalXianyang, KínaContact: Jiehong WangToborzás még nem indult
  • The Second Affiliated Hospital of Shanxi University of Chinese MedicineXianyang, KínaContact: Fengli ZhangToborzás még nem indult
  • Yangquan Coal Industry (Group) Co., Ltd. General HospitalYangquan, KínaContact: Jianming WangToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)

A vizsgálat 2 csoportja

  • Changkang granulesA vizsgált kezelés

    7.5g/bag, 1 bag per dose, 2 doses per day, oral,4 consecutive weeks.

  • Changkang granules PlaceboPlacebo, összehasonlításként

    7.5g/bag, 1 bag per dose, 2 doses per day, oral,4 consecutive weeks.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial, Efficacy and Safety Study of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea ( Liver qi Affecting the Spleen Pattern)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06753890: ki vehet részt
A regiszteradat frissítve
2024. december 31.